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tant cost-driving factor was drug acquisition (median HC:
€260, CC: €293). Signiﬁcantly fewer prescriptions have
been detected in the HC for ACE-inhibitors, diuretics,
digitalis, and beta-blockers. HRQL was improved signif-
icantly in both years over two years, the improvement
was slightly better in HC; however, no signiﬁcant differ-
ences could be detected. Therefore a conduct of a CUA
is not yet possible. Safety and efﬁcacy in HC have been
assessed signiﬁcantly better by the treating physicians.
CONCLUSIONS: According to German guidelines, ACE-
inhibitors are recommended as ﬁrst-line therapy for CHF.
The data show that in some cases this conventional
therapy may be replaced by hawthorn-extract with the
same or slightly better outcome. The ﬁnal results of the
study are expected for 2003.
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OBJECTIVE: To compare two methods of assessing costs
of pharmacological treatment of CVI: based on a resource
utilization questionnaire and on a global estimation of
expenditure declared by patients. METHODS: The study
of costs associated with CVI in Poland was performed on
a representative sample of 1000 people over 18 from the
general population. In patients suffering from CVI, data
concerning all the costs related to this illness were col-
lected by trained interviewers. Among the many ques-
tions, patients were asked about oral and local medicines
consumed (in units), as well as about their own global
estimation of monthly expenditure on treatment. Finally,
the costs calculated in the two different ways were com-
pared. Different cost groups: compression therapy, 
surgical and cosmetic operations, diagnostic tests, hospi-
talisation and indirect costs were measured in the tradi-
tional way (and not compared). RESULTS: One hundred
thirty-six people received oral treatment for CVI. The
average global estimation of monthly expenditure on oral
treatment was €16.82. Monthly expenditure based on
resources consumed was equal to €6.12. Local medicines
were used by 186 people. The average global estimation
of monthly expenditure for local treatment was €9.32
compared to €3.08 when calculated on resource utiliza-
tion basis. CONCLUSIONS: The patients’ perception on
how much they spend on their treatment differs to a great
extent from the cost of medicines calculated on a resource
utilisation basis. The cost of treatment can be assessed
accurately on a basis of a well designed resource utilisa-
tion questionnaire and unit cost.
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OBJECTIVES: CHF is a disease associated with high
morbidity and mortality. Some 1–2% of the total health-
care budget is consumed in the management of CHF. Hos-
pital costs account for up to 70% of this expenditure and
readmission rates for patients with a primary diagnosis
of CHF can be as high as 50% within 6 months of being
discharged. The use of spironolactone in patients with
severe CHF, as demonstrated in the RALES study, has
been shown to reduce mortality by 30% and the rate of
hospitalisation by 35%. In this study the cost effective-
ness of spironolactone plus standard therapy compared
with the use of conventional treatment alone was deter-
mined. An investigation of prescribing trends of spirono-
lactone in general practice in Ireland was undertaken to
determine the impact of the evidence from the RALES
study. METHODS: The study was performed through the
design of a Markov model. The cost data and mortality
and hospital readmission rates for patients on standard
therapy were obtained from a cohort of patients attend-
ing our hospital over a 12-month period. Outcome data
for the spironolactone arm was obtained from the RALES
study. A community prescription database was used 
to analyse prescribing trends for spironolactone from
January 1998 to November 2001. RESULTS: The incre-
mental cost effectiveness ratio (ICER) for spironolactone
therapy was €466 per life year gained (LYG). Sensitivity
analysis demonstrates an ICER range of €75/LYG to
€1136/LYG under a variety of assumptions. A threefold
rise in the proportion of patients prescribed spironolac-
tone following the publication of the RALES study was
observed. CONCLUSIONS: Following publication of the
RALES study a threefold increase in the number of pre-
scriptions for spironolactone has been observed. This
study suggests that the use of spironolactone for patients
with severe CHF is cost effective in the Irish healthcare
setting.
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OBJECTIVES: Atherosclerosis is a disease with relevant
epidemiologic and economic consquences; in 1999,
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260.000 atherosclerosis-related hospitalizations occurred
in Italy. There is evidence that Amlodipine treatment is
effective in reducing the health burden of atherosclerosis
and the objective of this analysis is to assess the pharma-
coeconomic proﬁle of Amlodipine in atherosclerotic
disease and in the Italian scenario. METHODS: Alterna-
tives: standard care plus Amlodipine besylate treatment
vs standard care alone in patients with CAD identiﬁed by
angiography in Italy. Perspective: National Health Service
(NHS). Technique: cost-effectiveness analysis on 2 hypo-
thetical cohorts of 1000 subjects; an incremental cost 
per patient free for events has been calculated. Time: 36
months. All effects and costs were discounted with an
annual rate of 5%. Costs: drugs and direct medical costs
quantiﬁed by using NHS tariffs expressed in €2002.
Effects: measured through the results from the PREVENT
study (Pitt B et al, 2000): i.e. fatal acute myocardial
infarction (AMI) or not, fatal stroke or not, congestive
heart failure, unstable angina, CABG and PTCA.
RESULTS: Treating the hypotethical cohort of 1000 sub-
jects with Amlodipine resulted in a total cost of
€2,896,345 (€1,267,472 for pharmacological treatment
and €1,628,873 for treating 355 events). Treating the
hypotethical cohort of 1000 subjects with placebo
resulted in a total cost of €2,643,732 to follow 547
events. The treatment with Amlodipine was superior
regarding the development of any ﬁrst event (206 with
Amlodipine and 284 with placebo) and the incremental
cost per patient free for events was €3,235. CONCLU-
SIONS: The results indicate that Amlodipine therapy is
more effective and more costly than placebo and that a
drug investment with Amlodipine leads to a signiﬁcant
reduction of the health burden of atherosclerotic disease.
The incremental health beneﬁt can be obtained at an
affordable cost.
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OBJECTIVE: The AVERT study (Atorvastatin versus
Revascularization Treatment) showed the beneﬁts of the
aggressive treatment with Atorvastin (ATV) 80mg/day in
reducing the incidence of ischemic events. The objective
of this analysis was to compare the associated costs of
ATV-80mg vs Percutaneous Coronary Intervention (PCI)
using unit costs from Spain. METHODS: This Econom-
ical Evaluation (EE) compared the total expected cost and
cost-effectiveness of treatment with ATV-80mg daily
versus PCI, for 18 months. 341 patients (pts) with stable
coronary artery disease were randomized to receive
medical treatment with ATV-80mg/day (164pts), or 
to undergo the recommended PCI followed by usual 
care including lipid-lowering treatments (177pts). The
primary outcome was ischemic cardiovascular events. 
EE has been performed from a 3rd payer perspective (the
National Health Services, with 2001 costs). The cost of
ATV-80mg used was twice ATV-40mg (€2.64 per tablet)
currently marketed. RESULTS: The 164pts included in
ATV-group suffered 36 events (22pts) with hospitaliza-
tion and the 177pts in PCI-group, 61 events (37pts). The
Total Cost in ATV-group was €378,853.31: sum of Ator-
vastatin-80mg Treatment Total Cost: 233,798,40€and all
Inpatient Events Cost: €145,054.91 (in this amount is
included 18 PCIs as event: €76,676.40). The Total Cost
in PCI-group was €1,075,647.82: sum of PCI Total Cost:
€753,984.60, all Inpatient Events Cost €280,504.42
(included 21 PCIs as event in this group: €89,455.80),
and Concomitant Lipid-lowering Treatment Cost:
€41,158.80. Therefore the Cost Per Event in ATV-group
was €2,310.08 and 6,077.11€ in PCI-group, with a dif-
ference of €3,767.03 per event more in the PCI-group.
The Incremental Cost Per Event Avoided was 
-€30,107.16 in the ATV-group. CONCLUSIONS: In
low-risk patients with stable coronary artery disease,
aggressive lipid-lowering therapy with ATV-80mg/day is
at least as effective as angioplasty, after 18 months of
follow-up, and it is cost-saving to the National Health
Services.
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OBJECTIVE: To compare the economic consequences of
antihypertensive treatment with perindopril (1 ¥ 4mg)
and enalapril (2 ¥ 10mg). METHODS: The clinical, epi-
demiological and economic data were derived from a sci-
entiﬁc project conducted in the whole of Poland among
GPs, and concerned 438 patients treated in mono-therapy
within the last year. Calculations were made from the
societal perspective and the retrospective approach was
applied. The direct medical costs of: pharmacological
treatment, doctors’ consultations, hospitalisation, labora-
tory and diagnostic tests were identiﬁed and calculated.
Indirect costs were also assessed by the capital cost
method. Effectiveness was measured by the percentage of
the patients with appropriate blood pressure control
according to the ﬁrst deﬁnition (BP£140/90mmHg) and
the second deﬁnition, (BP < 140/90mmHg), consistent
with JNC VI guidelines. RESULTS: Effectiveness, mea-
sured according to the ﬁrst deﬁnition was 52,45% in the
perindopril group and 41,03% in the enalapril group.
